Protection Against Parkinson's Disease Progression: Clinical Experience

Neurotherapeutics

Volumn 5, Issue 2, 2008, Pages 210-225

  LeWitt, Peter A ^a,b   Taylor, Danette C ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

clinical trials; disease modification; neurodegeneration; neuroprotection; Parkinson's disease

Indexed keywords

10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIPARKINSON AGENT; ASCORBIC ACID; CEP 1347; CGP 3466 B; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; GPI 1485; LAZABEMIDE; LEVODOPA; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; NEURTURIN; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; SELEGILINE; TCH 346; UBIDECARENONE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; LOADING DRUG DOSE; MITOCHONDRIAL ENERGY TRANSFER; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DOPAMINE AGONISTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 41249090400     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.01.007     Document Type: Article

References (117)

1. Anderson D.W., Bradbury K.A., and Schneider J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 24 (2006) 3174-3182
2. Hirsch E.C. How to judge animal models of Parkinson's disease in terms of neuroprotection. J Neural Transm Suppl 70 (2006) 255-260
3. Ravina B.M., Fagan S.C., Hart R.G., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
4. Suchowersky O., Gronseth G., Perlmutter J., Reich S., Zesiewicz T., Weiner W.J., and Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. [Erratum in: Neurology. 2006;67:299]. Neurology 66 (2006) 976-982
5. Goetz C.G., Koller W.C., Poewe W., et al. Management of Parkinson's disease: an evidence-based review. Mov Disorders 17 Suppl 4 (2002) S1-S166 (abstracts).
6. Goetz C.G., Poewe W., Rascol O., and Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disorders 20 (2005) 523-529
7. Fearnley J., and Lees A.J. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
8. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46 (1989) 1052-1060
9. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1989) 1364-1371
10. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176-183
11. Shults C.W., Haas R.H., and Beal M.F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 9 (1999) 267-272
12. Tarnopolsky M.A., and Beal M.F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 49 (2001) 561-574
13. Lipton S.A., Gu Z., and Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 82 (2007) 1-27
14. Deutch A.Y. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. J Neural Transm Suppl 70 (2006) 67-70
15. Zigmond M.J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease?. Insights from an animal model of parkinsonism. Neurobiol Dis 4 (1997) 247-253
16. Fahn S., Oakes D., Shoulson I., et al., Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
17. Fahn S., Elton R.L., and Members of the UPDRS Development Committee. Recent developments in Parkinson's disease. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Unified Parkinson Disease Rating Scale Vol. 2 (1987), Macmillan Healthcare Information, Florham Park, NJ 153-164
18. Shults C.W., Oakes D., Kieburtz K., et al., Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson's disease: evidence for slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
19. Guimaraes P., Kieburtz K., Goetz C.G., Elm J.J., Palesch Y.Y., Huang P., Ravina B., Tanner C.M., and Tilley B.C. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials 2 (2005) 509-518
20. Goetz C.G., Fahn S., Martinez-Martin P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 22 (2007) 41-47
21. Ravina B., Eidelberg D., Ahlskog J.E., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 (2005) 208-215
22. Marek K., Jennings D., and Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression?. Eur J Neurol 9 Suppl 3 (2002) 15-22
23. 123I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 32 (2005) 1452-1456
24. Eckert T., Tang C., and Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6 (2007) 926-932
25. Huang C., Tang C., Feigin A., et al. Changes in network activity with the progression of Parkinson's disease. Brain 130 (2007) 1834-1846
26. Elm J.J., Goetz C.G., Ravina B., et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 57 (2005) 197-203
27. Peterson A.L., and Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5 (2008) 270-280
28. Spencer J.P., Jenner A., Butler J., et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 24 (1996) 95-105
29. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S26-S38
30. Heikkila R.E., Terleckyj I., and Sieber B.A. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J Neural Transm Suppl 32 (1990) 217-227
31. Giladi N., McDermott M.P., Fahn S., et al., Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56 (2001) 1712-1721
32. Djaldetti R., Ziv I., and Melamed E. The effect of deprenyl washout in patients with long-standing Parkinson's disease. J Neural Transm 109 (2002) 797-803
33. LeWitt P.A., Oakes D., Cui L., and Parkinson Study Group. The need for levodopa as an endpoint of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol. Mov Disord 12 (1997) 183-189
34. Ward C.D. Does selegiline delay progression of Parkinson's disease?. A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57 (1994) 217-220
35. Mäki-Ikola O., and Heinonen E. Study design problems of DATATOP study analysis. Ann Neurol 40 (1986) 946-948
36. Tetrud J.W., and Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245 (1989) 519-522
37. Myllylä V.V., Sotaniemi K.A., Vuorinen J.A., and Heinonen E.H. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand Suppl 136 (1991) 70-72
38. Pålhagen S., Heinonen E.H., Hägglund J., et al., Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51 (1998) 520-525
39. Pålhagen S., Heinonen E., Hägglund J., et al. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 66 (2006) 1200-1206
40. Larsen J.P., Boas J., Erdal J.E., and The Norwegian-Danish Study Group. Does selegiline modify the progression of early Parkinson's disease?. Results from a five-year study. Eur J Neurol 6 (1999) 539-547
41. Tatton W., Chalmers-Redman R., and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110 (2003) 509-515
42. Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Arch Neurol 51 (1994) 342-347
43. LeWitt P.A., Segel S.A., Mistura K.L., and Schork M.A. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 16 (1993) 332-337
44. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 40 (1996) 99-107
45. Akao Y., Youdim M.B., Davis B.A., Naoi M., and Rabey J.M. Rasagiline mesylate, a new MAO B inhibitor for the treatment of Parkinson's disease. a double-blind study as adjunctive therapy to levodopa. J Neurochem 78 (2001) 727-735
46. Maruyama W., Akao Y., Carrillo M.C., et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24 (2002) 675-682
47. Mandel S., Grunblatt E., Riederer P., et al. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17 (2003) 729-762
48. Youdim M.B., Amit T., Bar-Am O., Weinstock M., and Yogev-Falach M. Amyloid processing and signal transduction properties of anti-Parkinson-anti-Alzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 993 (2003) 378-386
49. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study. Arch Neurol 59 (2002) 1937-1943
50. Carlile G.W., Chalmers-Redman R.M.E., Tatton N.A., et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric gluteraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57 (2000) 2-12
51. Stocchi F., Vacca L., Grassini P., et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67 Suppl 2 (2006) S24-S29
52. Olanow C.W., Schapira A.H., LeWitt P.A., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
53. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23 (2000) 34-44
54. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. JAMA 284 (2000) 1931-1938
55. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
56. Whone A.L., Watts R.L., Stoessl A.J., et al., REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
57. Oertel W.H., Wolters E., Sampaio C., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 21 (2006) 343-353
58. Felten D.L., Felten S.Y., Fuller R.W., et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging 13 (1992) 339-351
59. Ferger B., Teismann P., and Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 883 (2000) 216-223
60. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
61. Hall E.D., Andrus P.K., Oostveen J.A., et al. Neuroprotective effects of pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Mov Disord 11 Suppl 1 (1996) 191 (abstract)
62. Vu T.Q., Ling Z.D., Ma S.Y., et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 107 (2000) 159-176
63. Sethi V.H., Wu H., and Oostveen J.A. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 754 (1997) 181-186
64. Cassarino D.S., Fall C.P., Smith T.S., and Bennett Jr. J.P. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71 (1998) 295-301
65. Kitamura Y., Kosaka T., Kakimura J.I., et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 54 (1998) 1046-1054
66. Zou L., Xu J., Jankovic J., He Y., Appel S.H., and Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 281 (2000) 167-170
67. Le W.D., Jankovic J., Xie W., and Appel S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107 (2000) 1165-1173
68. Carvey P., Pieri S., and Ling Z. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104 (1997) 209-228
69. Ling Z.D., Robie H.C., Tong C.W., and Carvey P.M. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 289 (1999) 202-210
70. Anderson D.W., Neavin T., Smith J.A., and Schneider J.S. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 905 (2001) 44-53
71. Abramova N.A., Cassarino D.S., Khan S.M., Painter T.W., and Bennett Jr. J.P. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 67 (2002) 494-500
72. Takata K., Kitamura Y., Kakimura J., Kohno Y., and Taniguchi T. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res 872 (2000) 236-241
73. Tanaka K., Miyazaki I., Fujita N., Haque M.E., Asanuma M., and Ogawa N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 26 (2001) 31-36
74. Brooks D.J., Frey K.A., Marek K.L., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184 Suppl 1 (2003) S68-S79
75. 18F-dopa PET study. J Neural Transm 109 (2002) 1433-1443
76. LeWitt P., Aizenman E., Newcomer T., Loeffler D., and Parkinson Study Group. The search for an endogenous neurotoxin in Parkinson's disease: TOPA and TOPA-quinone. Mov Disord 9 (1994) 482 abstract
77. Maharaj H., Sukhdev Maharaj D., Scheepers M., Mokokong R., and Daya S. L-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 1063 (2005) 180-186
78. Olanow C.W., Agid Y., Mizuno Y., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 (2004) 997-1005
79. Camp D.M., Loeffler D.A., and LeWitt P.A. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 74 (2000) 1229-1240
80. Chan P.L., Nutt J.G., and Holford N.H. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 24 (2007) 791-802
81. Fahn S. A pilot trial of high-dose α-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 Suppl (1992) S128-S132
82. Canet-Avilés R.M., Wilson M.A., Miller D.W., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101 (2004) 9103-9108
83. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68 (2007) 20-28
84. 10 in the MPTP model of parkinsonism. J Neurochem (2007) 8 [Epub ahead of print]
85. Matthews R.T., Ferrante R.J., Klivenyi P., et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157 (1999) 142-149
86. Constantinescu R., McDermott M.P., Dicenzo R., et al. A randomized study of the bioavailability of different formulations of coenzyme Q10 (ubiquinone). J Clin Pharmacol 47 (2007) 1580-1586
87. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson's disease. Neurology 69 (2007) 1480-1490
88. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671
89. Bender A., Koch W., Elstner M., et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67 (2006) 1262-1264
90. Waldmeier P., Bozyczko-Coyne D., Williams M., and Vaught J.L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72 (2006) 1197-1206
91. Du Y., Ma Z., Lin S., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98 (2001) 14669-14674
92. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 (2002) 1763-1771
93. He Y., Appel S., and Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909 (2001) 187-193
94. Diguet E., Fernagut P.O., Wei X., et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19 (2004) 3266-3276
95. Ishitani R., Kimura M., Sunaga K., Katsube N., Tanaka M., and Chuang D.M. An antisense oligonucleotide to glyceraldehyde-3-phosphate-dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 278 (1996) 447-454
96. Ishitani R., Sunaga K., Hirano A., Saunders P., Katsube N., and Chuang D.M. Evidence that glyceraldehyde-3-phosphate-dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 66 (1996) 928-935
97. Kragten E., Lalande I., Zimmermann K., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273 (1998) 5821-5828
98. Andringa G., and Cools A.R. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. J Neural Transm Suppl 60 (2000) 215-225
99. Maroney A.C., Glicksman M.A., Basma A.N., et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 18 (1998) 104-111
100. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 62 (2004) 330-332
101. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 (1994) 613-622
102. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
103. Rascol O., Olanow C.W., Brooks D., et al. A 2-year multicenter placebo-controlled, double blind parallel group study of the effect of riluzole in Parkinson's disease. Mov Disord 17 Suppl 5 (2002) 39 (abstract)
104. Jankovic J., and Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 8 (2002) 271-276
105. Vatassery G.T., Fahn S., Kuskowski M.A., and Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 50 (1998) 1900-1902
106. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 52 (1995) 237-245
107. Carlsson T., Björklund T., and Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 7 (2007) 109-120
108. Herzog C.D., Dass B., Holden J.E., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22 (2007) 1124-1132
109. Gasmi M., Herzog C.D., Brandon E.P., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 15 (2007) 62-68
110. Xue Y.Q., Zhao L.R., Guo W.P., and Duan W.M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 146 (2007) 1245-1258
111. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. [Erratum in: Hum Gene Ther 2005;16:400]. Hum Gene Ther 16 (2005) 262-270
112. Mochizuki H. Gene therapy for Parkinson's disease. Expert Rev Neurother 7 (2007) 957-960
113. Ren Y., Liu W., Jiang H., Jiang Q., and Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 280 (2005) 34105-34112
114. Hunter R.L., Dragicevic N., Seifert K., et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100 (2007) 1375-1386
115. Chen H., Zhang S.M., Hernán M.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
116. Benner E.J., Mosley R.L., Destache C.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 9435-9440
117. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80 (2002) 262-270